Diagnostic usefulness of the Janus kinase 2 mutation in non BCR/ABL myeloproliferative disorders

Korean Journal of Internal Medicine

Volumn 21, Issue 4, 2006, Pages 219-224

  Bang, Soo Mee ^a   Ahn, Jeong Yeal ^a   Park, Jiyoon ^a   Yoo, Soo Jin ^a   Park, Se Hoon ^a   Nam, Eun Mi ^a   Park, Pil Whan ^a   Seo, Yiel Hea ^a   Cho, Eun Kyung ^a   Shin, Dong Bok ^a   Lee, Jae Hoon ^a  

^a Gachon University   (South Korea)

Author keywords

Chronic idiopathic myelofibrosis; Essential thrombocythemia; Janus kinase 2 mutation; Myeloproliferative disorders; Polycythemia vera

Indexed keywords

BCR PROTEIN, HUMAN; BIOLOGICAL MARKER; BREAKPOINT CLUSTER REGION PROTEIN; DNA; JANUS KINASE 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CASE REPORT; DIFFERENTIAL DIAGNOSIS; FEMALE; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; MUTATION; MYELOPROLIFERATIVE DISORDER; ONCOGENE; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; DNA; FEMALE; GENES, ABL; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; MYELOPROLIFERATIVE DISORDERS; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-BCR; RETROSPECTIVE STUDIES;

EID: 33846965612     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2006.21.4.219     Document Type: Article

References (25)

1. Vardiman JW, Brunning RD, Harris NL. Chronic myeloproliferative diseases: introduction. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. WHO classification of tumors: tumors of hematopoietic and lymphoid tissues. p. 17-19, Lyon, IARC Press, 2001
2. Tefferi A, Gilliland DG. The JAK2 V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis. Mayo Clin Proc 80:947-958, 2005
3. Bartram CR, de Klein A, Hagemeijer A, van Agthoven T, Geurts van Kessel A, Bootsma D, Grosveld G, Ferguson-Smith MA, Davies T, Stone M, Heitsterkamp N, Stephenson JR, Groffen J. Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 306:277-280, 1983
4. Pierre R, Imbert M, Thiele J, Vardiman JW, Brunning RD, Flandrin G. Polycythemia vera. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. WHO classification of tumors: tumors of hematopoietic and lymphoid tissues. p. 32-34, Lyon, IARC Press, 2001
5. Thiele J, Pierre R, Imbert M, Vardiman JW, Brunning RD, Flandrin G. Chronic idiopathic myelofibrosis. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. WHO classification of tumors: tumors of hematopoietic and lymphoid tissues. p. 35-38, Lyon, IARC Press, 2001
6. Imbert M, Pierre R, Thiele J, Vardiman JW, Brunning RD, Flandrin G. Essential thrombocythaemia. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. WHO classification of tumors: tumors of hematopoietic and lymphoid tissues. p. 39-41, Lyon, IARC Press, 2001
7. Murphy S. Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia. Semin Hematol 36:9-13, 1999
8. Thiele J, Kvasnicka HM. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients. Ann Hematol 82:148-152, 2003
9. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054-1061, 2005
10. James C, Ugo V, le Couedic JP, Staerk J, Delhommeau F, Lacout C, Garcon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434:1144-1148, 2005
11. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC. A gain of function mutation in JAK2 is frequently found in patients with myeloproliferative disorders. N Engl J Med 352:1779-1790, 2005
12. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BP, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, Andrea AD, Frohling S, Dohner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia,and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387-397, 2005
13. Witthuhn BA, Quelle FW, Silvennoinen O, Yi T, Tang B, Miura O, Ihle JN. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 74:227-236, 1993
14. Luo H, Hanratty WP, Dearolf CR. An amino acid substitution in the Drosophila hopTum-l Jak kinase causes leukemia-like hematopoietic defects. EMBO J 14:1412-1420, 1995
15. Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz SB, Zhao ZJ. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 280:22788-22792, 2005
16. Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL, Gilliland DG, Tefferi A. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood 106:1207-1209, 2005
17. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, Score J, Seear R, Chase AJ, Grand FH, White H, Zoi C, Loukopoulos D, Terpos E, Vervessou EC, Schultheis B, Emig M, Ernst T, Lengfelder E, Hehlmann R, Hochhaus A, Oscier D, Silver RT, Reiter A, Cross NC. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106:2162-2168, 2005
18. Levine RL, Loriaux M, Huntly BJ, Loh ML, Beran M, Stoffregen E, Berger R, Clark JJ, Willis SG, Nguyen KT, Flores NJ, Estey E, Gattermann N, Armstrong S, Look AT, Griffin JD, Bernard OA, Heinrich MC, Gilliland DG, Druker B, Deininger MW. The JAK2 V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 106:3377-3379, 2005
19. Lee JW, Kim YG, Soung YH, Han KJ, Kim SY, Rhim HS, Min WS, Nam SW, Park WS, Lee JY, Yoo NJ, Lee SH. The JAK2 V617F mutation in de novo acute myelogenous leukemias. Oncogene 25:1434-1436, 2006
20. Thiele J, Kvasnicka HM. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients. Ann Hematol 82:148-152, 2003
21. Sirhan S, Fairbanks VF, Tefferi A. Red cell mass and plasma volume measurements in polycythemia: evaluation of performance and practical utility. Cancer 104:213-215, 2005
22. Mossuz P, Girodon F, Donnard M, Latger-Cannard V, Dobo I, Boiret N, Lecron JC, Binquet C, Barro C, Hermouet S, Praloran V. Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. Haematologica 89:1194-1198, 2004
23. Breccia M, Morano SG, D'Andrea M, Russo E, D'Elia GM, Alimena G. Budd-Chiari syndrome as the first manifestation of polycythemia vera in young women with inherited thrombophilic state: an aggressive form of myeloproliferative disorder requiring multidisciplinary management. Eur J Haematol 75:396-400, 2005
24. Thiele J, Kvasnicka HM, Diehl V. Initial (latent) polycythemia vera with thrombocytosis mimicking essential thrombocythemia. Acta Haematol 113:213-219, 2005
25. Tefferi A, Spivak JL. Polycythemia vera: scientific advances and current practice. Semin Hematol 42:206-220, 2005